Lyssavirus antigen constructs

Active Publication Date: 2020-07-16
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides a new type of self-amplifying RNA molecule that can be used as a vaccine. These molecules do not contain a protein capsid and are therefore safer and easier to produce. This reduces the risk of creating dangerous infectious viruses and makes it easier to scale up for commercial production.

Problems solved by technology

A neurotropic virus, it enters the nervous system of its host, causing an encephalomyelitis that is almost invariably fatal.
While inserting RNA formulated merely with a buffer, i.e., naked RNA, into a cell can induce both gene expression and an immune response, the in vivo instability of naked RNA limits its potency as a vaccine.
Furthermore, the hydrophilicity and strong negative charge of RNA impedes its uptake into cells.
While Lyssavirus prophylaxis is currently available, high numbers of doses are required both pre- and post-exposure, and compliance is low, which diminishes the medical benefit.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lyssavirus antigen constructs
  • Lyssavirus antigen constructs
  • Lyssavirus antigen constructs

Examples

Experimental program
Comparison scheme
Effect test

example 2

Expression of SAM Lyssaviral Antigens

[0342]Western blot analysis was performed to determine whether the transgenes were expressed from the SAM rabies constructs. BHK cells (1×106) were transfected with 2.5 ug RNA from Constructs 1-4. After 20 hours, cell extracts were harvested and the production of rabies G protein was analysed by SDS gel electrophoresis followed by western blot analysis with the mouse anti-rabies glycoprotein antibody MAB8727 (Millipore Sigma, Billerica Mass., US). After incubation with primary antibody, the membrane was washed and then incubated with the peroxidase-conjugated anti-mouse antibody 115-035-003 (Jackson ImmunoResearch Laboratories, Inc., West Grove Pa., US). Finally the assay was developed by electrochemiluminescence (ECL) using standard techniques (GE Healthcare RPN2106, Little Chalfont, UK).

[0343]FIG. 2A demonstrates that BHK cells transfected with Constructs 1-4 all expressed rabies G protein. Molecular weight standards showing the location of 39 ...

example 3

mmunogenicity

[0345]The immunogenicity of the SAM rabies constructs was evaluated in parallel with RABAVERT in BALB / c mice (FIG. 3A and FIG. 3B). Each of the four constructs shown in FIG. 1A and Table 1 was formulated with either a cationic nanoemulsion (CNE) or a lipid nanoparticle (LNP). The animals were immunized on days 0 and 21 with the SAM vaccine constructs and on days 0, 7 and 21 with RABAVERT, according to the licensed RABAVERT dosing schedule. Each group consisted of 10 mice. Sera were collected on days 14 and 35 to evaluate the animals' immunogenicity against rabies. Serology was performed by the micro rapid Fluorescent Focus Inhibition Test for rabies (RFFIT) to determine the titer of anti-rabies neutralizing antibodies (nAb) (Smith et al. Bull. World Health Organ. 48:535 (1973)). The World Health Organization (WHO) guidelines recommend using the RFFIT to determine nAb titers and considers an Ab titer of 0.5 IU / ml to be an adequate response to a rabies vaccine (WHO Positi...

example 4

s Vaccines Provide Long-Term Immunogenicity

[0349]The ability of SAM rabies vaccines to confer long term immunogenicity was examined and the results are shown in FIG. 4. Construct 4 was formulated in amounts of 1.5 ug with CNE (square), 0.15 ug with LNP (triangle) or 1.5 ug with LNP (inverted triangle). RABAVERT (circle) was administered in three doses on days 0, 7 and 21 at a dilution factor of 1 / 25 of the human clinical dose. Neutralizing antibody titers of mice immunized with each of these formulations were measured by RFFIT at days 56, 90 and 180 days post-immunization. The dotted line denotes the threshold of immunogenicity for a rabies vaccine of 0.5 IU / ml.

[0350]At day 14, 1.5 ug Construct 4 RNA formulated with CNE, 0.15 ug Construct 4 RNA formulated with LNP or 1.5 ug Construct 4 RNA formulated with LNP elicited neutralizing antibodies to rabies at levels well above the immunogenicity threshold of effectiveness. By day 35 and at subsequent time points, the LNP-formulated SAM v...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Timeaaaaaaaaaa
Login to View More

Abstract

Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity.

Description

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH[0001]This invention was made with United States government support under Agreement No. HR0011-12-3-0001 awarded by DARPA. The government has certain rights in the invention.FIELD OF THE INVENTION[0002]This invention is in the field of treating and preventing viral diseases. In particular, the present invention relates to self-amplifying RNA molecules encoding a Lyssavirus antigen. It includes the use of Lyssavirus antigens for treating and preventing rabies.BACKGROUND TO THE INVENTION[0003]Lyssavirus is an enveloped, single-stranded RNA virus in the Rhabdoviridae family. Members of the Lyssavirus genus cause rabies and have the highest fatality rate of all known human viral pathogens. Rabies is transmitted via the saliva of infected mammals. A neurotropic virus, it enters the nervous system of its host, causing an encephalomyelitis that is almost invariably fatal. Currently there are about 60,000 rabies deaths worldwide yearly, mostly...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/205A61K9/127
CPCA61K2039/53A61K9/127A61K39/205A61K39/12C12N15/86C12N2760/20134C12N2770/36143Y02A50/30
InventorHASHEY, KATHRYNMALYALA, PADMASAMSA, MARCELOSLACK, OLGAYU, DONGSTOKES, ALANJALAH, RASHMI
OwnerGLAXOSMITHKLINE BIOLOGICALS SA